Kuwait: Clinical Trial for influenza drug Avigan to begin
A potential treatment for the COVID-19 disease caused by the novel coronavirus will have a clinical trial for the influenza drug Avigan. It will begin in Kuwait as early as this month, informed sources said Monday.
Data collected through the trial may be used in applications for approval of the drug. Avigan has been proposed as a possible treatment for the disease caused by the novel coronavirus.
Up to 1,000 people are expected to participate in the trial to confirm the efficacy and safety of the drug as a remedy to the novel coronavirus.
The trial will be led by Indian generic drug maker Dr. Reddy’s Laboratories Ltd., with whom Fujifilm Corp. has signed a licensing contract for the overseas manufacturing and sales of Avigan. The Japanese company will support the trial by supplying the drug.
Fujifilm Toyama Chemical Co., the Fujifilm subsidiary that developed Avigan, began a clinical trial in Japan in late March with a target of 96 participants.
Earlier this month, Fujifilm said it had granted exclusive rights to Dr. Reddy’s to develop, produce and sell the drug as a potential COVID-19 treatment overseas along with Dubai-based Global Response Aid.
Kuwait had logged over 59,763 COVID-19 cases as of Monday with 559 new cases and 652 recoveries.